Drug Topics

JULY 18, 2025

News FDA Updates Law and Advocacy Technology Trends Viewpoints All News Media In-Depth Insights Pharmacist View Script-Ed Expert Interviews Podcasts Conferences Conference Coverage Conference Listing Resources Disease Awareness White Board Video American Pharmacists Month Sponsored Resources CME/CE Partners Publications Drug Topics Journal Total Pharmacy Journal Submission of Articles Events Virtual Events Total Pharmacy Solutions Summit Business Business Strategies Patient Services Pharmacy Inv

Specialty Pharmacies

Pharmacy Times

JULY 18, 2025

ImCheck's ICT01 gains an orphan drug designation from the FDA, offering hope for acute myeloid leukemia (AML) treatment in older patients with limited options.

FDA

Drug Topics

JULY 18, 2025

IQVIA’s Lead Director of Research Michael Kleinrock discusses how federal policy has been impacting prescription drug costs in the US and where those trends are expected to go.

Pharmacy Times

JULY 18, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice in Focus: Oncology Pharmacy Practice in Focus: Health Systems Pharmacy Careers All Publications About the Publications Author Submission Submit to

HIV Treatment and Prevention Agents

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Drug Topics

JULY 18, 2025

News FDA Updates Law and Advocacy Technology Trends Viewpoints All News Media In-Depth Insights Pharmacist View Script-Ed Expert Interviews Podcasts Conferences Conference Coverage Conference Listing Resources Disease Awareness White Board Video American Pharmacists Month Sponsored Resources CME/CE Partners Publications Drug Topics Journal Total Pharmacy Journal Submission of Articles Events Virtual Events Total Pharmacy Solutions Summit Business Business Strategies Patient Services Pharmacy Inv

Specialty Pharmacies

Hospital Pharmacy Europe

JULY 18, 2025

People in England will be among the first in Europe to access a new once-daily treatment for cystic fibrosis, following a recommendation in final draft guidance from the National Institute for Health and Care Excellence (NICE). The triple combination medicine vanzacaftor/tezacaftor/deutivacaftor (brand name Alyftrek), which is manufactured by Vertex Pharmaceuticals, was licensed for use in the UK in March 2025 and will now become available immediately through the NHS in England.

Hospitals

Pharmacy Times

JULY 18, 2025

The updated version 1.2026 NCCN Guidelines for chronic myeloid leukemia (CML) emphasize individualized treatment strategies, TKI-specific considerations, drug interaction management, and pregnancy safety, highlighting the critical role of oncology pharmacists in optimizing therapy selection, patient counseling, and cost-effective care.

Drug Topics

JULY 18, 2025

News FDA Updates Law and Advocacy Technology Trends Viewpoints All News Media In-Depth Insights Pharmacist View Script-Ed Expert Interviews Podcasts Conferences Conference Coverage Conference Listing Resources Disease Awareness White Board Video American Pharmacists Month Sponsored Resources CME/CE Partners Publications Drug Topics Journal Total Pharmacy Journal Submission of Articles Events Virtual Events Total Pharmacy Solutions Summit Business Business Strategies Patient Services Pharmacy Inv

Vaccines

Hospital Pharmacy Europe

JULY 18, 2025

The Government has laid out plans to ‘modernise’ pharmacy supervision rules, after the proposed changes to aseptic services divided opinion. Proposed amendments to the Medicines Act 1968 and The Human Medicines Regulations 2012 are intended to free up pharmacist time by allowing registered pharmacy technicians to take on more responsibility in different pharmacy settings.

Hospitals

Pharma Marketing Network

JULY 18, 2025

In an era where attention is fleeting and data is overflowing, how can pharmaceutical marketers break through the noise? The answer isn’t just doing more with less. Today, Pharma Marketing AI empowers teams to do more—with more data, more channels, and more personalization. The transformation is no longer a luxury; it’s a necessity for reaching both healthcare providers (HCPs) and patients more meaningfully.

HIPAA

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Pharmacy Times

JULY 18, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice in Focus: Oncology Pharmacy Practice in Focus: Health Systems Pharmacy Careers All Publications About the Publications Author Submission Submit to

FDA

Drug Topics

JULY 18, 2025

News FDA Updates Law and Advocacy Technology Trends Viewpoints All News Media In-Depth Insights Pharmacist View Script-Ed Expert Interviews Podcasts Conferences Conference Coverage Conference Listing Resources Disease Awareness White Board Video American Pharmacists Month Sponsored Resources CME/CE Partners Publications Drug Topics Journal Total Pharmacy Journal Submission of Articles Events Virtual Events Total Pharmacy Solutions Summit Business Business Strategies Patient Services Pharmacy Inv

Health and Personal Care Stores

PQA

JULY 18, 2025

Welcome to Five For Friday! PQA is developing its next strategic plan, Blueprint PQA 2030, which will guide the organization’s work from 2026 through 2030. The proposed goals build on and continue key elements of PQA’s current strategic plan, Blueprint PQA 2025 and will be the focus of the 2025 PQA Leadership Summit. PQA now seeks input from its members on the goals and their objectives through Friday, August 8.

Independent Pharmacies

Pharmaceutical Technology

JULY 18, 2025

Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh

Packaging

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Pharmacy Times

JULY 18, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice in Focus: Oncology Pharmacy Practice in Focus: Health Systems Pharmacy Careers All Publications About the Publications Author Submission Submit to

Compounding Pharmacies

Pharmafile

JULY 18, 2025

Johnson & Johnson has submitted a supplemental New Drug Application to the US Food and Drug Administration (FDA) for Caplyta (lumateperone) to prevent relapse in adults with schizophrenia. It is currently approved by the FDA to treat the brain disorder. The submission is supported by data from a phase 3 study demonstrating that patients taking […] The post Johnson & Johnson submits FDA application for Caplyta to prevent schizophrenia relapse appeared first on Pharmafile.

FDA

Pharmacy Times

JULY 18, 2025

Researchers unveil a groundbreaking method using polypurine hairpins to inhibit PCSK9, offering a promising alternative for lowering cholesterol and reducing cardiovascular risk.

Pharmaceutical Commerce

JULY 18, 2025

In the fourth part of this roundtable discussion, a panel of subject matter experts dive into data exchange challenges relating to the Drug Supply Chain Security Act.

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Pharmacy Times

JULY 18, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice in Focus: Oncology Pharmacy Practice in Focus: Health Systems Pharmacy Careers All Publications About the Publications Author Submission Submit to

Compounding

Pharmaceutical Commerce

JULY 18, 2025

In the fourth part of his Pharma Commerce video interview, Sean O’Hearen, founder and principal consultant at 1st Line Partners, describes the prominence of underreporting falsified medicines.

PharmaVoice

JULY 18, 2025

In a push for “radical transparency” the FDA released 200 CRLs for drugs that were later approved — some of which are now public for the first time.

FDA

Pharmacy Times

JULY 18, 2025

The advisory committee cited concerns around ocular toxicity and overall tolerability, raising serious questions about the drug's benefit-risk profile ahead of its scheduled Prescription Drug User Fee Act action date on July 23, 2025.

FDA

The Checkup by Singlecare

JULY 18, 2025

Ubrelvy (ubrogepant) is a brand-name medication that is approved by the U.S. Food and Drug Administration (FDA) for the acute treatment of migraine, with or without aura, in adults. Ubrelvy is very effective at stopping a migraine headache in its tracks. The ACHIEVE I and II clinical trials found that a significantly higher proportion of people taking ubrogepant felt better and were able to function normally within two hours of taking the medication, compared to a placebo (inactive treatment).

FDA

Pharmaceutical Technology

JULY 18, 2025

The FDA has approved GSK's Shingrix vaccine (recombinant zoster vaccine or RZV) in a prefilled syringe presentation to prevent shingles.

FDA

Drug Topics

JULY 18, 2025

Perceptions of pharmacy as a long-term career have evolved significantly in recent years due to shifts in education, work roles, and workplace challenges.

European Pharmaceutical Review

JULY 18, 2025

Boehringer Ingelheim and LEO Pharma have agreed a partnership deal to advance development and commercialisation of the innovative monoclonal antibody Spevigo ® (spesolimab). It is the first drug approved for generalised pustular psoriasis flares that specifically targets the IL-36 pathway. It is a rare and potentially life-threatening skin disease, the companies shared.

Pharmaceutical Technology

JULY 18, 2025

Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh

FDA

Pharmacy Times

JULY 18, 2025

The National Comprehensive Cancer Network (NCCN) has updated its ovarian cancer guidelines version 3.2025 to recommend niraparib as maintenance therapy for patients with BRCA wild-type or homologous recombination (HR)–deficiency who did not receive bevacizumab during primary treatment.

Pharmaceutical Technology

JULY 18, 2025

Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh

Packaging

Pharmacy Times

JULY 18, 2025

The National Comprehensive Cancer Network (NCCN) has released multiple myeloma guidelines version 2.2026 to include linvoseltamab as a preferred treatment for heavily pretreated patients, highlighting its intravenous formulation, dosing options, and streamlined Risk Evaluation and Mitigation Strategy program.

Pharmaceutical Technology

JULY 18, 2025

Pharmaceutical companies and manufacturers, including MilliporeSigma (Burlington, US), Simtra BioPharma Solutions (Parsippany, US), Carbogen AMCIS (Bubendorf, Switzerland), and BioNTech (Mainz, Germany), have recently invested to meet growing demand for antibody drug conjugates (ADCs) as targeted cancer treatments.

Pharmaceutical Companies

Pharmafile

JULY 18, 2025

After completing a safety review of Ixchiq – a vaccine for chikungunya – the European Medicines Agency’s (EMA) safety committee has agreed to lift the temporary restriction on its use in people aged 65 years and older. However, the vaccine should now only be used in individuals of all ages where there is a significant […] The post EMA lifts temporary ban on chikungunya vaccine Ixchiq following safety review appeared first on Pharmafile.

Vaccines

Pharmaceutical Technology

JULY 18, 2025

Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh

FDA